Softgel

CV Sciences, Inc. Launches New Line of THC-Free Gummies and Softgels

Retrieved on: 
Tuesday, March 21, 2023
Balance, Cannabinoid, OTCQB, Minimum daily balance, Military personnel, SAN, Occupation, The Non-GMO Project, THC, Safety, Dietary supplement, Softgel, CBD

SAN DIEGO, March 21, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusCBD™Daily Balance THC-Free Gummies and Softgels. These new additions to the +PlusCBD™ product portfolio are now available for purchase at +PlusCBD.

Key Points: 
  • The +PlusCBD™Daily Balance THC Free line offers a daily-use supplement that provides the wellness benefits of CBD without THC and other cannabinoids.
  • +PlusCBD™Daily Balance THC-Free Gummies and Softgels are made with CV Sciences' 99.9% pure CBD isolate, expertly crafted in concentrations that help consumers overcome intense challenges to their everyday mental and physical wellbeing.
  • "Sometimes, consumers just want to experience the relaxing effects of CBD without THC," said Joseph Dowling, CEO of CV Sciences.
  • The +PlusCBD™ Daily Balance THC Free line is intended for daily use to help consumers reach their personal wellness goals.

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Retrieved on: 
Saturday, March 18, 2023
Attack, Hereditary angioedema, Safety, Bradykinin receptor B2, Softgel, II, Pain, HAE, Oral, United Kingdom, Conference, Pharmaceutical industry

The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.

Key Points: 
  • The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.
  • 74 participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
  • Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, 20 mg=10.7%, 30 mg=6.5%, placebo=60.8%).
  • The presentation slides will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Sky Wellness Wins 2023 Product of the Year Award for Most Innovative Product in CBD

Retrieved on: 
Wednesday, March 1, 2023
Ernst & Young Entrepreneur of the Year Award, CPG, Softgel, Collection, Melatonin, Retail, Sleep, Partnership, Research, Commerce, Food Lion, Tractor Supply Company, CBN, Cannabinoid, Albertsons, Safeway, Turkey, Convenience store, Kantar, Petroleum News, CSP, Pharmaceutical industry, C-Store, CBD

PHOENIX, March 1, 2023 /PRNewswire/ -- For the second year, the team at Sky Wellness landed a coveted Product of the Year Award with the 2023 recognition going to Sky Wellness CBD Sleep Gummies , a premium THC-free, broad-spectrum CBD+CBN sleep aid.

Key Points: 
  • PHOENIX, March 1, 2023 /PRNewswire/ -- For the second year, the team at Sky Wellness landed a coveted Product of the Year Award with the 2023 recognition going to Sky Wellness CBD Sleep Gummies , a premium THC-free, broad-spectrum CBD+CBN sleep aid.
  • 40,000 American shoppers voted it as the most innovative product in the CBD category this year.
  • The collection of CBD sleep aid products by Sky Wellness is formulated with the perfect combination of CBD, CBN, and melatonin.
  • For further information about Sky Wellness CBD Sleep Gummies, visit skywellnes.com .

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Retrieved on: 
Friday, February 24, 2023
Translational medicine, Pharmacology, Safety, Bradykinin receptor B2, American Academy, Softgel, Fraunhofer Society, Hereditary angioedema, United Kingdom, AAAAI, Oral, Attack, II, HAE, Berlin, Bradykinin, Poster, Pharmaceutical industry, Dermatology, Immunology

Today, people living with HAE must inject themselves either subcutaneously or intravenously when treating HAE swellings.

Key Points: 
  • Today, people living with HAE must inject themselves either subcutaneously or intravenously when treating HAE swellings.
  • 74 participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
  • Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, 20 mg=10.7%, 30 mg=6.5%, placebo=60.8%).
  • Following the data presentation on February 26, the poster and audio recording will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

High Tide Releases Audited 2022 Financial Results Featuring Record Fourth Quarter Revenue of $108.2 Million and Record Adjusted EBITDA of $5.0 Million

Retrieved on: 
Tuesday, January 31, 2023
Agriculture, Natural Resources, Cannabis, Other Natural Resources, Bank statement, Manitoba Liquor & Lotteries Corporation, Government, Softgel, Legislation, Acquisition, Nature, World Vision International, EBITDA, EDGAR, SEDAR, News, Business, Sale, Letter, CBD, High Tide, Anomaly, ELITE, LOI, FSE, Ontario Cannabis Retail Corporation, Partnership, CAD, High, Cryptocurrency, Video game, Drug, Silviculture

In the fourth quarter of fiscal 2022, revenue was $93.9 million in Canada (an increase of 16% sequentially), $13.2 million in the United States (an increase of 4% sequentially), and $1.2 million internationally (a decrease of 37% sequentially).

Key Points: 
  • In the fourth quarter of fiscal 2022, revenue was $93.9 million in Canada (an increase of 16% sequentially), $13.2 million in the United States (an increase of 4% sequentially), and $1.2 million internationally (a decrease of 37% sequentially).
  • Sequentially, Cabanalytics data sales increased to $6.4 million from $5.5 million in the third fiscal quarter
    The Company’s bricks-and-mortar locations generated same-store sales growth of 50% year-over-year and 9% sequentially in the fourth fiscal quarter of 2022.
  • High Tide stands for great experience and expertise in building retail cannabis brand strategies like no other player.
  • For the New Cannabis Ventures’ senior listing, segmented cannabis-only sales must generate more than US$25 million per quarter (CAD$31 million) – for full details, see: https://www.newcannabisventures.com/cannabis-company-revenue-ranking/
    Selected financial information for the fourth quarter and year ended October 31, 2022:

High Tide Releases Audited 2022 Financial Results Featuring Record Fourth Quarter Revenue of $108.2 Million and Record Adjusted EBITDA of $5.0 Million

Retrieved on: 
Tuesday, January 31, 2023
Financial statement, FSE, ConnectFirst Credit Union, LOI, World Vision International, EBITDA, Ontario Cannabis Retail Corporation, AB, Legislation, ELITE, News, Bank statement, Letter, Anomaly, EDGAR, Government, Partnership, Sale, CBD, Manitoba Liquor & Lotteries Corporation, Cannabis, Cannabis shop, CAD, Acquisition, High Tide (band), Creditor, High Tide, Softgel, Business, SEDAR, Video game, Mail order, Cryptocurrency, Drug, Retail, Silviculture

In the fourth quarter of fiscal 2022, revenue was $93.9 million in Canada (an increase of 16% sequentially), $13.2 million in the United States (an increase of 4% sequentially), and $1.2 million internationally (a decrease of 37% sequentially).

Key Points: 
  • In the fourth quarter of fiscal 2022, revenue was $93.9 million in Canada (an increase of 16% sequentially), $13.2 million in the United States (an increase of 4% sequentially), and $1.2 million internationally (a decrease of 37% sequentially).
  • Sequentially, Cabanalytics data sales increased to $6.4 million from $5.5 million in the third fiscal quarter
    The Company's bricks-and-mortar locations generated same-store sales growth of 50% year-over-year and 9% sequentially in the fourth fiscal quarter of 2022.
  • High Tide stands for great experience and expertise in building retail cannabis brand strategies like no other player.
  • For the New Cannabis Ventures' senior listing, segmented cannabis-only sales must generate more than US$25 million per quarter (CAD$31 million) – for full details, see: https://www.newcannabisventures.com/cannabis-company-revenue-ranking/
    Selected financial information for the fourth quarter and year ended October 31, 2022:

Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, December 8, 2022
Asthma, R, Intellectual property, Annual report, PD, Research, Absorption, Softgel, Bradykinin, Food, FDA, Attack, Book, Record, ACAAI, Safety, Executive Committee, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hereditary angioedema, Trial of the century, American College of Allergy, Asthma and Immunology, Human, International Accounting Standards Board, Security (finance), Research and development, American College, HAE, Union, Patient, Association of International Accountants, Human resources, Administration, Degenerative disease, COVID-19, Pharmaceutical industry, Vaccine

Today Pharvaris announced top-line Phase 2 data demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.

Key Points: 
  • Today Pharvaris announced top-line Phase 2 data demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.
  • R&D expenses were €14.1 million for the quarter ended September 30, 2022, compared to €9.0 million for the quarter ended September 30, 2021.
  • G&A expenses were €8.3 million for the quarter ended September 30, 2022, compared to €4.4 million for the quarter ended September 30, 2021.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

Making the Holiday Season Brighter for Friends of Karen

Retrieved on: 
Tuesday, December 6, 2022
New York metropolitan area, Powder, Organic, BBB, Capsule, Charity Navigator, Parent, Tablet, Sibling, Friends, Clothing, Softgel, Toy

HAUPPAUGE, N.Y., Dec. 6, 2022 /PRNewswire-PRWeb/ -- Marking its sixth donation to Friends of Karen over the past several years, Makers Nutrition is filling the holiday wish lists of five children assisted by the non-profit for their 2022 holiday Adopt-a-Family season.

Key Points: 
  • Marking its sixth donation to Friends of Karen over the past several years, Makers Nutrition is filling the holiday wish lists of five children assisted by the non-profit for their 2022 holiday Adopt-a-Family season.
  • HAUPPAUGE, N.Y., Dec. 6, 2022 /PRNewswire-PRWeb/ -- Marking its sixth donation to Friends of Karen over the past several years, Makers Nutrition is filling the holiday wish lists of five children assisted by the non-profit for their 2022 holiday Adopt-a-Family season.
  • These gift cards will help children with life-threatening illnesses and their siblings make this holiday brighter.
  • We are just so proud to help make that happen for Friends of Karen this holiday season."

Joy Organics Launches Black Friday Sale Early This Year

Retrieved on: 
Tuesday, November 15, 2022
Sale, Absorption, Cyber Monday, USDA, CMO, Cram, Softgel, CBD, Glossary of cannabis terms

FORT COLLINS, Colo., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Joy Organics announced its Holiday Sale event today.

Key Points: 
  • FORT COLLINS, Colo., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Joy Organics announced its Holiday Sale event today.
  • Starting now, the Colorado-based premium CBD brand is offering a 30% discount on its entire product line until Nov. 28 (Cyber Monday).
  • "To save our customers that hassle of cramming all their shopping into just a couple stressful days, we've decided to take a more relaxed approach by offering a steep discount for nearly two weeks," says Gerrid Smith, Joy Organics' co-founder and CMO.
  • To learn more about Joy Organics' premium lines of USDA Certified Organic, THC-enhanced, and rigorously-tested CBD products, visit their website at joyorganics.com.

Global Softgel Capsule Market Report 2022: Increased Number of Clinical Trials Supporting Softgel Capsule Use to Drive Revenue Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
Health, Pharmaceutical, APIS, Taste, CCRT, Trial of the century, HPMC, Starch, Absorption, Analysis, IP, MEA, Patent, Patient, Projection, Manufacturing, USD, Safety, Application, Softgel, Intellectual property, Stomach, Capsule, Pregnancy, Organization, Risk, BTC, Pharmaceutical industry

The "Global Softgel Capsule Market, By Type, By Application, By Manufacturers & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Softgel Capsule Market, By Type, By Application, By Manufacturers & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Softgel capsules have several advantages, including ease of ingesting, odour and taste masking, improved absorption, higher bioavailability, and superior atmospheric stability.
  • Global Softgel capsule market is segmented based on type, application, manufacturers, and region:
    Based on type, market is segmented into gelatin/animal based, non animal.
  • The increasing number of clinical trials testing the efficacy of soft gelatin capsules in the treatment of various disorders is a significant factor fueling market expansion.